Enliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its earnings results on Thursday. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07, Zacks reports. The company had revenue of $0.03 million during the quarter.

Enliven Therapeutics Trading Up 2.2 %

Shares of ELVN stock opened at $20.74 on Friday. The business’s 50 day moving average is $21.59 and its two-hundred day moving average is $23.80. Enliven Therapeutics has a twelve month low of $10.90 and a twelve month high of $30.03. The company has a market capitalization of $1.01 billion, a P/E ratio of -10.92 and a beta of 1.04.

Insider Buying and Selling at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total value of $66,332.50. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $265,330. This represents a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,784 shares of company stock worth $1,092,375. 29.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of research analyst reports. Robert W. Baird lifted their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Enliven Therapeutics has an average rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.